USPTO serial 79384325
MICROCAPS
Reviewed by CopyMark Law Group
Status 402
- Filing date
- Status date
- Registration date
- —
- Examiner
- SANTOMARTINO, MARTHA L
- Law office
- TMO LAW OFFICE 112
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with MICROCAPS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
ROBERT S. BRODER
ROBERT S. BRODER COLLARD & ROE, P.C.1077 NORTHERN BLVD.ROSLYN, NY 11576UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical, veterinary and sanitary products, namely, drug delivery agents in the form of specialized tablets, orally disintegrating tablets, minitablets, microtablets, minitablets and microtablets comprising multiparticulates, filled capsules, lozenges, powders, granules, granulates, sprinkles, sachets, patches, pads, suppositories, creams, gels, ointments, paste, emulsions, suspensions, syrups, elixirs, drops, liquids, skin lotions, vaccines and injectables used for the treatment of disorders or diseases in the gastrointestinal tract, in the digestive system, in the gut, in the immune systems, in the cardiovascular system, in the respiratory tract, in the blood, in the metabolism, in the nervous system, in the cognition, in the behavior, and in the reproductive tract, gastrointestinal infections, diarrhea, irritable bowel syndrome, inflammatory bowel syndrome disease, enterocolitis, enteritis, ulcerative colitis, cardiovascular disorders, hypertension, thrombosis, vasoconstriction, asthma, inflammation of respiratory tract, bronchoconstriction, thrombocythemia, hypertriglyceridemia, hypercholesterolemia, hyperlipoproteinemia, blood anemia, hypocalcemia, diabetes, diabetic peripheral neuropathy, dyskinesia, hyperkinetic movements, enzyme deficiency, pancreatitis, pancreatectomy, steatorrhea, cystic fibrosis, Paget's disease, bacterial infections, viral infections, fungal infections, osteoporosis, cancer, mucosal and systemic inflammation, functional disease, abdominal pain, allergy, obesity, muscle spasticity, spasms, convulsion, dysthymia, schizophrenia, degenerative dementia, Alzheimer's, stress, anxiety, depression, mood disturbance, sociability disturbance, sleep disturbance, psychological disturbance, attention deficit hyperactivity disorder, addiction, fibromyalgia, obsessive-compulsive disorders, pain, peripheral neuropathic pain, post-surgical pain, back-pain, osteoarthritis; inhalers for medical purposes sold filled with pharmaceutical, veterinary and sanitary preparations for treating asthma, pulmonary hypertension, inflammation of respiratory tract, bronchoconstriction, plasmodium infections and fungal infections | SECTION 70 - CANCELLED | — |
| 040 | Manufacturing services to the order and specification of others of drug dosage forms, drug compositions, drug formulations, drug delivery agents in the nature of tablets, orally disintegrating tablets, minitablets, microtablets, minitablets and microtablets comprising multiparticulates, capsules, lozenges, powders, granules, granulates, sprinkles, sachets, patches, pads, suppositories, creams, gels, ointments, paste, emulsions, suspensions, syrups, elixirs, drops, liquids, skin lotions, vaccines, injectables, aerosols, and sanitary products, all in the pharmaceutical and the veterinary fields; clinical manufacturing of drug compositions for others to support clinical trials | SECTION 70 - CANCELLED | — |
| 042 | Research and development services in the pharmaceutical and the veterinary fields; product design and development of pharmaceutical preparations including powder and granules for suspension in liquids, semisolid forms, solid forms, capsules, tablets, sachets, sprinkles; research and development in the area of drug delivery systems with customized release, taste masked release, controlled release; technological consultancy services in the field of new product development | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 30, 2025 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Nov 30, 2025 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Oct 23, 2025 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Oct 23, 2025 | MAB1 | ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT | — |
| Oct 23, 2025 | ABN1 | ABANDONMENT - EXPRESS MAILED | — |
| Oct 22, 2025 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| May 17, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| May 12, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 12, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 12, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 29, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 29, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Apr 28, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 28, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 25, 2025 | ALIE | ASSIGNED TO LIE | — |
| Apr 8, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 8, 2025 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Apr 8, 2025 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Apr 8, 2025 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Dec 5, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 5, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Dec 5, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 5, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 5, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 5, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 8, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 8, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 8, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 24, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 24, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 24, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 24, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 2, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 2, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 15, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 14, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 9, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 5, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 1, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 30, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |